Table 1.
Genotype | Period (hr) | Power | Rhythmic% | N |
---|---|---|---|---|
UASMAN1/+ | 23.8 ± 0.0 | 90 ± 5 | 96 | 76 |
cryGAL4-39/UASMAN1 | 26.4 ± 0.3*,† | 31 ± 6*,† | 64 | 28 |
UASMAN1/+; cryGAL4-16/+ | 26.8 ± 0.2*,† | 40 ± 7*,† | 66 | 32 |
UASLam/+ | 23.9 ± 0.0 | 87 ± 6 | 93 | 55 |
cryGAL4-39/UASLam | 23.8 ± 0.2† | 33 ± 7*,† | 73 | 22 |
UASLMNB1/+; cryGAL4-16/+ | 24.4 ± 0.2† | 5 ± 2*,† | 26 | 31 |
UASLBR/+ | 23.7 ± 0.0 | 59 ± 5 | 79 | 67 |
cryGAL4-39/UASLBR | 25.6 ± 0.1*,† | 44 ± 6† | 79 | 33 |
UASLBR/+; cryGAL4-16/+ | N/A | 1 ± 0*,† | 0 | 32 |
cryGAL4-39/+ | 24.8 ± 0.1 | 86 ± 5 | 93 | 57 |
cryGAL4-16/+ | 25.6 ± 0.1 | 86 ± 5 | 94 | 64 |
One-way ANOVA compared to UAS control lines, p < 0.001.
One-way ANOVA compared to GAL4 control lines, p < 0.001.